The Cedars-Sinai Heart Transplant Program is committed to being an active participant in the development of new treatments for end stage heart failure, the development of noninvasive methods to detect rejection, more effective immunosuppression drugs with fewer side effects to fight organ rejection, improved artificial hearts and mechanical assist devices to sustain critically ill patients until transplantation and the use of stem cell therapy to repair damaged heart muscle.
A staggering number of scientific breakthroughs have been made in recent years but these only become useful if they can be studied and integrated carefully into practice. Cedars-Sinai provides the infrastructure within which new treatments and diagnostic modalities are tested and, in turn, made available in the clinical care setting.
A multidisciplinary approach that combines expertise and clinical knowledge, information and data analysis technologies and the experience of principle investigators, physicians, nurses and research fellows is actively encouraged.
Click on the links here to view our current clinical trials and key publications: